Best Life Sciences Companies in Uusimaa, Finland
The 98 best Life Sciences companies in Uusimaa, Finland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nanoform.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Uusimaa
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Nanoform Provider of a platform for the development of nano particles | $48M | 28 mo ago | 158 | Jouko Yliruusi Co-Founder | WordPressApple iCloud MailMicrosoft 365+22 | — | — |
| 2 | Nexstim Provider of noninvasive brain stimulation for rehabilitating stroke patients | $30M | 100 mo ago | 37 | Mikko Karvinen Chief Executive Officer | TYPO3 CMSPHPSalesforce+12 | 135 patents Advanced navigated transcranial magnetic stimulation devices and therapeutic pulse protocols. | — |
| 3 | TILT Biotherapeutics Developer of oncolytic viral immunotherapies for solid tumors | $29M | 13 mo ago | 21 | Akseli Hemminki Chief Executive Officer | WordPressMySQLPHP+10 | 73 patents Oncolytic viral therapies and adoptive cell immunotherapies targeting cancer and microbiome. | — |
| 4 | Mendor Blood glucose monitoring device | $28M | 122 mo ago | 16 | — | — | 31 patents Blood glucose monitoring devices and calibrated test‑strip cartridge technologies | — |
| 5 | Desentum Developing novel types of allergen immunotherapy products (allergy vaccines) | $27M | 28 mo ago | 6 | Janne Janis Co-Founder | WordPressMySQLPHP+18 | 40 patents Thermosensitive hydrogel drug delivery systems and engineered hypoallergenic peanut protein therapeutics. | 3 job openings |
| 6 | Blueprint Genetics Provider of genetic diagnostics and clinical interpretation for hereditary diseases | $26M | 107 mo ago | 143 | Tero Pekka Alastalo Co-Founder | Cart FunctionalityWordPressApple iCloud Mail+26 | — | 1 launch |
| 7 | Valo Therapeutics Developer of immunotherapies for cancer and infectious disease | $25M | 15 mo ago | 20 | — | DrupalPHPNginx+11 | 61 patents Oncolytic viral vector platforms for cancer immunotherapy and vaccine development | — |
| 8 | Nightingale Provider of a metabolomic technology platform for blood analysis and research | $23M | 65 mo ago | 64 | — | VimeoApache HTTP ServerAmazon Web Services+14 | — | — |
| 9 | Aiforia Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas | $23M | 6 mo ago | 3 | Jukka Tapaninen CEO | HubSpot CMS HubApple iCloud MailGoogle Workspace+26 | — | — |
| 10 | Algorithmiq Developer of quantum algorithms for chemistry and life science applications | $20M | 1 mo ago | 24 | Sabrina Maniscalco Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+16 | 26 patents Quantum algorithms for expectation estimation, noise mitigation, and fermionic encoding in quantum computing | 1 expansion |
| 11 | Aplagon Heparin peptidoglycan mimetics for treating complications of vascular intervention-related blood vessel… | $19M | 16 mo ago | 1 | Riitta Lassila Co-Founder | — | 32 patents Heparin‑protein conjugate antithrombotic drugs for thrombocytopenia treatment | — |
| 12 | Mobidiag In vitro diagnostics for infectious diseases | $16M | 77 mo ago | 128 | — | — | 100 patents Rapid molecular diagnostic kits for detecting pathogenic bacteria and toxins via nucleic acid amplification | — |
| 13 | HVR Cardio Provider of mitral valve leakage therapeutics development services | $11M | 41 mo ago | — | Olli Keranen Founder & CSO | — | 75 patents Cardiac valve annuloplasty devices and catheter-based implantation systems | — |
| 14 | CurifyLabs Provider of digital 3D printing solutions for personalized medicine | $11M | 12 mo ago | 16 | Niklas Topelius Co-Founder | HubSpot CMS HubFacebook LoginLinkedin Sign-in+20 | 12 patents Advanced pharmaceutical formulation and dispensing systems, including blade‑free mixing and printable doses. | — |
| 15 | Synoste Limb lengthening device | $11M | 92 mo ago | 15 | Antti Ritvanen Founder & Product Development Director | — | 33 patents Wireless-powered orthopedic bone-lengthening implants and external force generation devices | — |
| 16 | Rappta Therapeutics Provider of a small molecule drug discovery platform for cancer | $11M | 68 mo ago | 11 | Sunjeet Sawhney Chief Executive Officer; Board Member | — | 28 patents Small-molecule aromatic PP2A modulators for therapeutic enzyme regulation | — |
| 17 | Woodcast Provider of wooden material for casting and occupational therapy | $11M | 134 mo ago | — | Jari Salo Founder | — | — | — |
| 18 | Linio Biotech Developer of medical device for skin and tissue regeneration | $10M | 30 mo ago | 11 | Timo Ylikomi Co-Founder & CMO | — | 13 patents Cell‑free adipose‑derived therapeutic preparations for regenerative and cosmetic medicine | — |
| 19 | Beddit Sleep tracker | $8M | 141 mo ago | 6 | — | — | 12 patents Non‑invasive sleep monitoring and quality assessment using physiological sensor data. | — |
| 20 | Sooma Oy Non-invasive neuromodulation therapies | $7M | 27 mo ago | 22 | — | Cart FunctionalityShopifyShop Pay+28 | 32 patents Non-invasive and implantable transcranial brain stimulation devices and electrodes | — |
| 21 | Oncos Therapeutics Provider of precision orthopaedics and musculoskeletal oncology solutions | $6M | 193 mo ago | 11 | — | WordPressMySQLPHP+23 | 62 patents Patents concentrated in health & consumer products | — |
| 22 | Pixieray Developer of technology for optical eyeglasses | $4M | 48 mo ago | 33 | Rebecca Melakari Co-Founder | — | 134 patents Patents concentrated in computing, sensing & instrumentation | — |
| 23 | Plexpress High throughput gene expression analysis | $4M | 170 mo ago | — | Juhani Lahdenpera CEO | — | — | — |
| 24 | PlexPress Tools for gene expression analysis | $4M | 170 mo ago | — | Juhani Lahdenpera Founder & CEO | — | — | — |
| 25 | Veri Provider of a continuous glucose monitor for measuring blood glucose levels | $4M | 60 mo ago | 48 | Verneri Jaamuru Co-Founder | PrismicSentryNode.js+29 | — | — |
| 26 | Arivin Developer of therapeutics for antimicrobial resistance infections | $4M | 9 mo ago | 2 | — | — | — | — |
| 27 | Askel Healthcare Developer of regenerative medicines for cartilage & bone tissue regeneration | $3M | 53 mo ago | 8 | Anne Haaparanta Co-Founder & CTO | — | 18 patents Patents concentrated in health & consumer products | — |
| 28 | PulseOn Heart rate monitoring wearable and app | $3M | 151 mo ago | 21 | Jaakko Hattula CTO | WordPressMySQLPHP+15 | 55 patents Wearable cardiac/arrhythmia monitoring with signal quality estimation and biometric strap technology. | 1 job opening |
| 29 | Optomeditech Products in the areas of intravenous catheters and blood collection needles | $2M | 138 mo ago | 3 | Ami Rubinstein CEO | — | 13 patents Integrated illuminated catheters and needles for vascular access and blood sampling | — |
| 30 | Zora Biosciences Provider of diagnostic solutions for cardiovascular diseases and cancer | $2M | 77 mo ago | 7 | — | — | 167 patents Lipidomic and ceramide biomarkers for cardiovascular disease diagnosis and risk stratification | — |
| 31 | TENBORON Developer of boron carrier antibodies for the treatment of cancer | $2M | 85 mo ago | 2 | Juha Jouhki Chief Executive Officer | — | 19 patents Boronated EGFR1‑targeted antibody conjugates for BNCT cancer therapy | — |
| 32 | Maculaser Developer of laser therapy for the treatment of retinal diseases | $1M | 0 mo ago | 5 | Jani Tirronen Co-Founder & CEO | — | 22 patents Ophthalmic temperature monitoring and electroretinogram signal acquisition for retinal therapy | — |
| 33 | GlucoModicum Developer of needle-free glucose monitoring technology for personal health solutions | $1M | 52 mo ago | 37 | Johan Bobacka Co-Founder | WordPressApple iCloud MailMicrosoft 365+16 | 34 patents Continuous glucose monitoring and interstitial fluid biosensor technologies | — |
| 34 | Uute Scientific Provider of natural extract products for treating immune-mediated diseases | $1M | 53 mo ago | 10 | Oliver Boldt Chief Sales Officer and Co-Founder | WordPress Block EditorwpBakeryWordPress+32 | — | — |
| 35 | Northern Antibiotics Early-stage Finnish biopharma company developing anti-infectives for severely drug resistant gram negative… | $1M | 153 mo ago | 1 | Martti Vaara Co-Founder | — | 89 patents Polymyxin-derived antibiotics with reduced toxicity and enhanced Gram‑negative activity | — |
| 36 | Veil Provider of AI and ML based big data analytics and data anonymization solutions | $1M | 46 mo ago | 12 | Tuomo Pentikainen CEO | WordPressApple iCloud MailGoogle Workspace+27 | — | — |
| 37 | Solu Cloud based platform for real time genomic pathogen surveillance and epidemiology | $1M | 36 mo ago | — | Timo Moilanen Co-Founder | WebflowSentryWistia+12 | — | 1 launch |
| 38 | MediSapiens Clinical insights through Bioinformatics | $1M | 192 mo ago | 12 | — | — | 21 patents Computational analysis of biological samples and genomic health assessment | — |
| 39 | Neurotar In vivo imaging and image analysis company | $644K | 145 mo ago | — | Katja Karelina CEO | Cart FunctionalityWooCommerceWordPress+24 | 5 patents Patents concentrated in health & consumer products | — |
| 40 | Euformatics Bioinformatics tools to interpret next-gen sequencing data | $391K | 47 mo ago | 20 | — | WordPress Block EditorWordPressMySQL+23 | — | — |
Top 12 Life Sciences companies in Uusimaa
#1
Series B · Helsinki, Uusimaa · founded 2020 · 24 employees$20Mraised▾
Developer of quantum algorithms for chemistry and life science applications. The company develops algorithms that integrate classical and quantum computers. These algorithms address complex problems in quantum chemistry. They also offer solutions for drug discovery and development, targeting rare diseases. The company publishes research in peer-reviewed journals.
- May 2026Series B$21.2M
- Jun 2023Series A$15M
- Feb 2022Seed$5M
#2
Public · Helsinki, Uusimaa · founded 2014 · 3 employees$23Mraised▾
Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas. It provides analysis of digital pathology images for pathologists and researchers. The products are aiforia create, aiforia on-demand, and aiforia cloud.
- Dec 2025Post IPO$4.9M
- Jun 2021Series B$15.4M
- Feb 2021Grant (prize money)$483.6K
- Nov 2019Grant (prize money)$2.3M
#3
Series B · Helsinki, Uusimaa · founded 2013 · 21 employees$29.1Mraised▾
Developer of oncolytic viral immunotherapies for solid tumors. It has patented technology which uses oncolytic viruses to enhance tumor infiltrating lymphocyte therapy and chimeric antigen receptor (CAR) T-cell therapy. The lead product is a cytokine-armed oncolytic adenovirus for platinum-resistant ovarian cancer and also include other therapies for solid tumor.
- May 2025Series B$25M
- Feb 2023Grant (prize money)$2.3M
- Feb 2023Series B$6.3M
- Jul 2022Grant (prize money)$2.2M
#4
Seed · Espoo, Uusimaa · founded 2018 · 5 employees$1.5Mraised▾
Developer of laser therapy for the treatment of retinal diseases. It has developed treatment solutions for common retinal diseases including dry age-related macular degeneration. It helps in temperature control of the macula during non-damaging laser treatments. The treatment solutions mechanisms treat the root causes of AMD that reduce oxidative stress, prevent the aggregation of proteins, improve the transport of nutrients, and enhance RPEs cytoprotective mechanisms.
- Feb 2021Seed$1.5M
#5
Series B · Helsinki, Uusimaa · founded 2016 · 20 employees$25.2Mraised▾
Developer of immunotherapies for cancer and infectious disease. The company uses immunogenic viruses as active carriers of tumor-specific peptides to direct the immune system to specifically target and kill cancer cells. The proprietary PeptiCRAd platform, an oncolytic adenovirus with immunogenic tumor peptides adsorbed onto the negatively charged viral capsid.
- Mar 2025Series B$20.6M
- Apr 2023Grant (prize money)$326.1K
- Nov 2021Series A$12.8M
- Feb 2020Seed$1.2M
#6
Series A · Helsinki, Uusimaa · founded 2021 · 16 employees$11.5Mraised▾
Provider of digital 3D printing solutions for personalized medicine. The company has developed a platform that enables sustainable, quality-controlled production of personalized medicine through its pharmaceutical printing technology. It is a smart drug formulation platform that incorporates cutting-edge technology to redefine the drug compounding process.
- May 2025Conventional Debt$1.1M
- May 2025Series A$7.6M
- Apr 2023Grant (prize money)$2.7M
- Jan 2023Grant (prize money)—
#7
Series A · Helsinki, Uusimaa · founded 2009 · 1 employees$19.5Mraised▾
Aplagon is a Finnish, preclinical stage biotech developing Heparin peptidoglycan mimetics for treating complications of vascular intervention-related blood vessel occlusions. The Heparin peptidoglycan mimetics, are called APACs and are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. APACs, which were discovered by Aplagon scientists, are indicated for the prevention and management of both the short- and long -term complications of vascular intervention-related blood vessel occlusions.
- Feb 2025Series A$7.2M
- Sep 2022Grant (prize money)$2.1M
- 2022Grant (prize money)$10.1M
- Dec 2018Seed—
#8
Seed · Espoo, Uusimaa · founded 2022 · 2 employees$3.5Mraised▾
Developer of therapeutics for antimicrobial resistance infections
- Sep 2025Seed$3.5M
#9
Public · Helsinki, Uusimaa · founded 2008 · 158 employees$47.5Mraised▾
Provider of a platform for the development of nanoparticles. The company uses its multi-patented Controlled Expansion of Supercritical Solutions (CESS) for the development of API nanoparticles directly from the solution. The technology is based on the bottom-up method of recrystallization. It increases the dissolution and bioavailability of nanoparticles and also helps to cross the blood-brain barrier (BBB) for the treatment of CNS disorders such as Alzheimer’s and Parkinson’s disease.
- Feb 2024Grant (prize money)—
- Mar 2021Post IPO$47.5M
#10
Series C · Espoo, Uusimaa · founded 2011 · 6 employees$26.7Mraised▾
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. By studying the molecular mechanism of the hypersensitivity reaction, the company has made discoveries that allow for improved design of immunotherapeutic products against common types of allergies. The company will be starting clinical trials for the first hypoallergens in 2017.
- Feb 2024Series C$12.9M
- Jan 2022Series B$9.1M
- Jul 2021Grant (prize money)$59.4K
- Dec 2018Grant (prize money)$2.1M
#11
Series B · Helsinki, Uusimaa · founded 2013 · 22 employees$6.6Mraised▾
Sooma Oy is developing a non-invasive brain stimulation device, a treatment option for major neurological and psychiatric disorders. Initial product tDCS targets major depressive disorder and is CE Marked.
- Mar 2024Series B$5.5M
- Jun 2022Grant (prize money)$52.4K
- Jul 2020Grant (prize money)$1.8M
- Dec 2019Grant (prize money)$278.7K
#12
Series A · Helsinki, Uusimaa · founded 2017 · 11 employees$9.8Mraised▾
Developer of medical device for skin and tissue regeneration. The company offers a cell-free tissue product for skin restoration and soft tissue repair such as scar repair, skin rejuvenation, and wound treatment.
- Nov 2023Series A$4.6M
- 2023Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.